Navigation Links
Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Date:9/15/2008

BERKELEY HEIGHTS, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced today that the independent Data Monitoring Board (DMB) for AGENDA, a Phase 3 trial of the Company's lead oncology product Genasense(R) (oblimersen sodium) Injection, has completed its review. During its review, the DMB evaluated safety data from the study and conducted an analysis for futility. With more than half of the initially planned number of patients now enrolled, the Board recommended that the trial continue to completion of full enrollment.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. A total of 300 patients are expected to enroll in AGENDA.

Genta will provide a pooled update of blinded data from AGENDA, compared with data obtained in this biomarker-defined population from the Company's previous Phase 3 trial (see below), at an international scientific meeting, Perspectives in Melanoma XII, that is scheduled for October 2-4, 2008.

"We remain quite pleased with the high investigator enthusiasm for AGENDA," said Dr. Loretta M. Itri, M.D., Genta's President, Pharmaceutical Development. "We currently anticipate that accrual will complete in the first quarter of 2009."

About AGENDA

AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during a large randomized study of DTIC with or without Genasense, known as study GM301. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
8. Kiwa Fertilizers Pass Independent Tests
9. Amarin Appoints Dr. William Mason as Lead Independent Director
10. China Pharma Appoints Three Independent Non-Executive Directors
11. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015 Seoul Semiconductor ... for various applications in the lighting market. ... installations of this technology in emerging markets such ... a wide range of applications such as streetlight ... decorative lighting. , First launched in 2005 the ...
(Date:4/23/2015)... , April 23, 2015 BioTE Medical President ... book "Age Healthier Live Happier - Avoiding Over-Medication through ... Age Management Medicine Group Conference at JW Marriott / ... ",Age Healthier Live Happier, is a welcomed ... over-medication and searching for a higher quality of life ...
(Date:4/23/2015)... LAKE FOREST, Calif. , April 23, 2015 ... provider of advanced cryogenic logistics solutions for the ... has further established its cryogenic logistics solutions within ... customer agreement with Yancey Farms to support the ... top German Sport horse Stallions. ...
(Date:4/23/2015)... April 23, 2015  Metanome, Inc., an industry ... company has changed its name to Diversigen, Inc.  ... as the single commercial source for the myriad ... on the diverse opportunities of the microbiome.  From ... accepts – including those that are difficult to ...
Breaking Biology Technology:Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Metanome Announces Corporate Name Change to Diversigen 2
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, ... National Institutes of Health (NIH) Director,s Opportunity Award for ... Better Treatments" under the American Recovery & Reinvestment Act ...
... Medicago Inc. (TSX: MDG), a biotechnology company focused ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... applications under the Patent Cooperation Treaty (PCT) that ... proteins and VLPs. "The extraction and ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 3Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 2Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 3
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Purdue University biochemist has demonstrated a process using nanotechnology ... which may help reduce drug side effects. W. ... developed a nanopolymer that can be coated with drugs, ... in the cells the drug has entered. Since they,re ...
... WEST LAFAYETTE, Ind. - Chemical changes in tree leaves ... climate change may reduce the availability of soil nutrients, ... an associate professor of forestry and natural resources, found ... tannin when exposed to hot, droughtlike conditions. Those tannins, ...
... an eco-friendly diesel fuel have more red lights in their ... completely green would not only bend the laws of physics, ... limited, and since we can,t use more than what Earth ... sources like algae," said Peter Pfromm, professor of chemical engineering ...
Cached Biology News:Nanopolymer shows promise for helping reduce cancer side effects 2Drought-exposed leaves adversely affect soil nutrients, study shows 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 4
... White solid. PROTECT FROM LIGHT. ... water soluble pyrimidinone compound that acts as ... of PARP (IC 50 = 200 ... rmPARP2, respectively) with little activity against the ...
... speed, timer, SB3, Fully adjustable mixing angle, ... holders to hold a number of different ... ideal for aerating cultures, keeping biological samples ... The rotator can be used in incubators ...
...
... The DNA Engine Opticon 2 real-time ... of LEDs for fluorescence excitation (470-505 nm) ... (523-543 nm, 540-700 nm). The Opticon 2 ... thermal cycler, which includes a thermal gradient ...
Biology Products: